

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

CORRECTIVE ASSIGNMENT

NATURE OF CONVEYANCE:

Corrective Assignment to correct the Nature of Conveyance previously recorded on Reel 015377 Frame 0745. Assignor(s) hereby confirms the Nature of Conveyance is an Assignment.

CONVEYING PARTY DATA

Name	Execution Date
Elan Pharmaceuticals, Inc.	11/03/2004

RECEIVING PARTY DATA

Name:	Transave, Inc.
Street Address:	11 Deer Park Drive
Internal Address:	Princeton Corporate Plaza IV
City:	Monmouth Junction
State/Country:	NEW JERSEY
Postal Code:	08852

PROPERTY NUMBERS Total: 33

Property Type	Number
Patent Number:	5231112
Patent Number:	5288499
Patent Number:	6352716
Patent Number:	5631394
Patent Number:	5677337
Patent Number:	5681589
Patent Number:	5415867
Patent Number:	5200393
Patent Number:	5897873
Patent Number:	5820848
Patent Number:	6086851
Patent Number:	5916588
Patent Number:	6090406

PATENT

500022746

REEL: 015748 FRAME: 0386

CH \$1320.00 5231112

Patent Number:	5380531
Patent Number:	5614216
Patent Number:	5811118
Patent Number:	5540936
Patent Number:	6596305
Patent Number:	5552155
Patent Number:	5766624
Patent Number:	5882678
Patent Number:	6120797
Patent Number:	6294191
Patent Number:	6087325
Patent Number:	6143716
Patent Number:	6339069
Patent Number:	6500461
Application Number:	09914615
Application Number:	10130951
Application Number:	10500932
Application Number:	10500933
Application Number:	10500977
Application Number:	09429694

# CORRESPONDENCE DATA

Fax Number: (617)832-7000  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 617 832 1000  
Email: mdiverdi@foleyhoag.com  
Correspondent Name: Michael J. DiVerdi  
Address Line 1: 155 Seaport Blvd  
Address Line 2: World Trade Center West  
Address Line 4: Boston, MASSACHUSETTS 02210

NAME OF SUBMITTER:	Michael J. DiVerdi
--------------------	--------------------

Total Attachments: 39  
source=Non Recordation Document#page1.tif  
source=Non Recordation Document#page2.tif  
source=Non Recordation Document#page3.tif  
source=Non Recordation Document#page4.tif  
source=Non Recordation Document#page5.tif  
source=Non Recordation Document#page6.tif  
source=Non Recordation Document#page7.tif

source=Non Recordation Document#page8.tif  
source=Non Recordation Document#page9.tif  
source=Non Recordation Document#page10.tif  
source=Non Recordation Document#page11.tif  
source=Non Recordation Document#page12.tif  
source=Non Recordation Document#page13.tif  
source=Non Recordation Document#page14.tif  
source=Non Recordation Document#page15.tif  
source=Non Recordation Document#page16.tif  
source=Non Recordation Document#page17.tif  
source=Non Recordation Document#page18.tif  
source=Non Recordation Document#page19.tif  
source=Non Recordation Document#page20.tif  
source=Non Recordation Document#page21.tif  
source=Non Recordation Document#page22.tif  
source=Non Recordation Document#page23.tif  
source=Non Recordation Document#page24.tif  
source=Non Recordation Document#page25.tif  
source=Non Recordation Document#page26.tif  
source=Non Recordation Document#page27.tif  
source=Non Recordation Document#page28.tif  
source=Non Recordation Document#page29.tif  
source=Non Recordation Document#page30.tif  
source=Non Recordation Document#page31.tif  
source=Non Recordation Document#page32.tif  
source=Non Recordation Document#page33.tif  
source=Non Recordation Document#page34.tif  
source=Non Recordation Document#page35.tif  
source=Non Recordation Document#page36.tif  
source=Non Recordation Document#page37.tif  
source=Non Recordation Document#page38.tif  
source=Non Recordation Document#page39.tif

## PATENT ASSIGNMENT

Electronic Version v1.1  
Stylesheet Version v1.1

11/22/2004  
500012673

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Notice of Non-Recordation of Document No. 500012603
CONVEYING PARTY DATA	
Name	Execution Date
Elan Pharmaceuticals, Inc.	11/03/2004
RECEIVING PARTY DATA	
Name:	Transave, Inc.
Street Address:	11 Deer Park Drive
Internal Address:	Princeton Corporate Plaza IV
City:	Monmouth Junction
State/Country:	NEW JERSEY
Postal Code:	08852
PROPERTY NUMBERS Total: 33	
Property Type	Number
Patent Number:	6352716
Patent Number:	5231112
Patent Number:	5288499
Patent Number:	5631394
Patent Number:	5677337
Patent Number:	5681589
Patent Number:	5415867
Patent Number:	5200393
Patent Number:	5897873
Patent Number:	5820848
Patent Number:	6086851
Patent Number:	5916588
Patent Number:	6090406
Patent Number:	5380531

CH \$1320.00 6352716

Patent Number:	5614216
Patent Number:	5811118
Patent Number:	5540936
Patent Number:	6596305
Patent Number:	5552155
Patent Number:	5766624
Patent Number:	5882678
Patent Number:	6120797
Patent Number:	6294191
Patent Number:	6087325
Patent Number:	6143716
Patent Number:	6339069
Patent Number:	6500461
Application Number:	09429694
Application Number:	09914615
Application Number:	10130951
Application Number:	10500932
Application Number:	10500933
Application Number:	10500977

## CORRESPONDENCE DATA

Fax Number: (617)832-7000

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 6178321000

Email: mdiverdi@foleyhoag.com

Correspondent Name: Michael J. DiVerdi

Address Line 1: 155 Seaport Blvd.

Address Line 4: Boston, MASSACHUSETTS 02210

NAME OF SUBMITTER:

Michael J. DiVerdi

Total Attachments: 24

source=Assignment#page1.tif

source=Assignment#page2.tif

source=Assignment#page3.tif

source=Assignment#page4.tif

source=Assignment#page5.tif

source=Assignment#page6.tif

source=Assignment#page7.tif

source=Assignment#page8.tif

source=Assignment#page9.tif

source=Assignment#page10.tif

Patent Number:	5415867
Patent Number:	5200393
Patent Number:	5897873
Patent Number:	5820848
Patent Number:	6086851
Patent Number:	5916588
Patent Number:	6090406
Patent Number:	5380531
Patent Number:	5614216
Patent Number:	5811118
Patent Number:	5540936
Patent Number:	6596305
Patent Number:	5552155
Patent Number:	5766624
Patent Number:	5882678
Patent Number:	6120797
Patent Number:	6294191
Patent Number:	6087325
Patent Number:	6143716
Patent Number:	6339069
Patent Number:	6500461
Application Number:	09429694
Application Number:	09914615
Application Number:	10130951
Application Number:	10500932
Application Number:	10500933
Application Number:	10500977

**CORRESPONDENCE DATA**

Fax Number: (617)832-7000  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 6178321000  
Email: mdiverdi@foleyhoag.com  
Correspondent Name: Michael J. DiVerdi  
Address Line 1: 155 Seaport Blvd.  
Address Line 4: Boston, MASSACHUSETTS 02210

**NAME OF SUBMITTER:**

Michael J. DiVerdi

Patent Number:	5614216
Patent Number:	5811118
Patent Number:	5540936
Patent Number:	6596305
Patent Number:	5552155
Patent Number:	5766824
Patent Number:	5882678
Patent Number:	6120797
Patent Number:	6294191
Patent Number:	6087325
Patent Number:	6143716
Patent Number:	6339069
Patent Number:	6500461
Application Number:	09429694
Application Number:	09914615
Application Number:	10130951
Application Number:	10500932
Application Number:	10500933
Application Number:	10500977

## CORRESPONDENCE DATA

Fax Number: (617)832-7000

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 617 832-1000

Email: mdiverdi@foleyhoag.com

Correspondent Name: Michael J. DiVerdi

Address Line 1: 155 Seaport Blvd

Address Line 4: Boston, MASSACHUSETTS 02210

NAME OF SUBMITTER:

Michael J. DiVerdi

Total Attachments: 21

source=Assignment#page1.tif

source=Assignment#page2.tif

source=Assignment#page3.tif

source=Assignment#page4.tif

source=Assignment#page5.tif

source=Assignment#page6.tif

source=Assignment#page7.tif

source=Assignment#page8.tif

source=Assignment#page9.tif

source=Assignment#page10.tif

## Form of Patent Assignment

THIS Assignment is effective as of November 1, 2004, by and between ELAN PHARMACEUTICALS, INC., a corporation duly organized under and pursuant to the laws of DELAWARE, and having its principal place of business at 800 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CALIFORNIA 94080 (hereinafter referred to as "the Assignor"); and Transave, Inc., a corporation duly organized under and pursuant to the laws of Delaware and having its principal place of business at Princeton Corporate Plaza IV, 11 Deer Park Drive, Suite 117, Monmouth Junction, NJ 08852-1923 (hereinafter referred to as "the Assignee") witnessed:

Whereas Assignor is the owner, as described below, of certain patents and patent applications as further described in Exhibit 1 hereof (hereinafter referred to as "the Patents");

Whereas, Assignee desires to acquire Assignor's right, title and interest in and to said patents or patent applications and in and to the said patents or patent applications in any and all countries;

Whereas, by virtue of an Assignment by the inventors to The Liposome Company, One Research Way, Princeton, New Jersey 08540, USA; and

Whereas Assignee, pursuant to a merger, evidenced by the Certificate of Merger issued by the State of Delaware, attached hereto as Exhibit 2, has acquired The Liposome Company, together with all right, title, and interest in the Patents, whether by recorded assignment, or by reason of the merger itself, the Assignor is the owner of the entire right, title and interest in and to said invention, the right to file applications on any inventions, and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon.

NOW, THEREFORE, in consideration of payments and other obligations as evidenced by the Patent Assignment Agreement of even date herewith, and other good and valuable consideration, and sufficiency of which are hereby acknowledged, Assignor assigns and transfers to the Assignee, and the Assignee's legal representatives, successors and assigns, and the Assignee accepts such assignment and transfer, all of the Assignor's right, title, and interest in and to the above-mentioned patents or patent applications, the right to file applications and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefor and thereon, and in and to any and all applications claiming priority to said applications, divisions, continuations, and continuations-in-part of said applications, and reissues and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own



use and behalf and the use and behalf of its successors, legal representatives, and assigns to the full end of the term or terms for which any said patent( s) may be granted, as fully and entirely as the same would have been held by the undersigned Assignors had this assignment and sale not been made.

AND, Assignor covenants that Assignee may at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem reasonably necessary or desirable to perfect the Assignee's enjoyment of this assignment, and render reasonable assistance in making application for and obtaining patents, or execute statements and other affidavits. It is understood that this agreement shall bind, and inure to the benefit of, the assigns and legal representatives of all parties hereto.

AND, Assignee shall have the sole responsibility for the prosecution and maintenance of the Patents from the date of this agreement above, including the payment of prosecution, issuance and maintenance fees, the docketing and tracking of any critical dates such as the due date of maintenance fees, re-examinations and reissues, and for the enforcement thereof and all other associated rights and responsibilities.

AND, Assignee does hereby release, discharge and hold harmless Assignor and their past, present and future employees, agents, officers, directors, shareholders, parents, subsidiaries, attorneys, successors- in- interest and assigns, or any of them, from and against any and all responsibility for the prosecution and maintenance of the Patents, including the payment of prosecution, issuance, and maintenance fees, the docketing and tracking of any critical dates such as the due date of maintenance fees, re-examinations and reissues, and for the enforcement thereof and all other associated rights and responsibilities.

AND the Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said Assignee, as Assignee of the entire right, title and interest, any and all patents which may be issued and granted on or as a result of the application aforesaid, to the Assignee as the Assignee of said invention and the Letters Patent or Patents issued and to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

IN WITNESS WHEREOF, and intending to be legally bound hereby, Assignor and Assignee have caused this Agreement to be signed and executed by the undersigned duly authorized officers as of the date of execution below.

ELAN PHARMACEUTICALS, INC.

SIGNED for and on behalf )  
of ELAN PHARMACEUTICALS, INC.)





Name: Carl W. Battle  
Title: Senior Vice President/  
Chief Patent Counsel

STATE OF CALIFORNIA )  
County of San Mateo ) ss

On this 3<sup>rd</sup> day November, 2004, before me, Denise Malatesta, personally appeared Carl W. Battle, personally known to me and proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument, and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.



Notary Public

Exhibit 2  
Certificate of Merger

01/30/2003 09:10 FAX 6508753620

002

*Delaware*

PAGE 1

*The First State*

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"THE LIPOSOME COMPANY, INC.", A DELAWARE CORPORATION,

WITH AND INTO "ELAN PHARMACEUTICALS, INC." UNDER THE NAME OF "ELAN PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWENTY-EIGHTH DAY OF DECEMBER, A.D. 2001, AT 10:02 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF MERGER IS THE THIRTY-FIRST DAY OF DECEMBER, A.D. 2001, AT 12 O'CLOCK A.M.



2104559 8100M  
020021366

*Harriet Smith Windsor*  
Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 1554941

DATE: 01-11-02

**Exhibit 1**  
**the Patents**

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-234	112	08/108,822	6,352,716	United States	Issued	3/5/19
033364-232	112	07/425,727	5,231,112	United States	Issued	1/26/05
033364-233	112	07/758,587	5,288,499	United States	Issued	1/26/05
033364-234	112	08/108,822	6,352,716	United States	Issued	3/5/19
033364-241	112	479,005	1,262,093	Canada	Issued	10/3/06
033364-242	112	491,321	1,262,334	Canada	Issued	10/17/06
033364-259	112	8-191707/1996	2706649	Japan	Issued	4/11/05
033364-263	112	60-504547	2061157	Japan	Issued	10/10/05
033364-261	112	5-268664	2568034	Japan	Issued	4/11/05
033364-262	112	7-231103/1995	2706642	Japan	Issued	4/11/05
033364-260	112	60-509020	2138894	Japan	Issued	4/11/05
033364-240	112	85902251.9	0185680	Belgium	Issued	4/11/05
033364-244	112	5735/85	n/a	Denmark	Pending	4/11/05
033364-245	112	5910/86	n/a	Denmark	Pending	10/10/05
033364-248	112	865021	92463	Finland	Issued	10/10/05
033364-249	112	85902251.9	0185680	France	Issued	4/11/05
033364-243	112	85902251.9	P3586242.4	Germany	Issued	4/11/05
033364-251	112	852352	852,352	Greece	Issued	9/26/05
033364-253	112	5039/85	203,205	Hungary	Issued	10/10/05
033364-254	112	2336/85	66709	Ireland	Issued	9/23/05
033364-258	112	85902251.9	0185680	Italy	Issued	4/11/05
033364-265	112	85902251.9	0185680	Luxembourg	Issued	4/11/05
033364-268	112	85902251.9	0185680	Netherlands	Issued	4/10/05
033364-269	112	864960	173,213	Norway	Issued	10/10/05

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-247	112	547326	547326	Spain	Issued	8/19/06
033364-246	112	553808	0553808	Spain	Issued	11/16/07
033364-250	112	85902251.9	0185680	United Kingdom	Issued	4/11/05
033364-252	112	0920714	0920714	Hong Kong	Issued	4/12/04
033364-275	112	9290767.4	9290767.4	Singapore	Issued	4/11/05
033364-239	112	44345/89	609647	Australia	Issued	10/10/05
033364-238	112	49528/85	596953	Australia	Issued	10/10/05
033364-255	112	74912	74912	Israel	Issued	4/16/05
033364-256	112	76600	76600	Israel	Issued	10/6/05
033364-257	112	96444	96444	Israel	Issued	10/6/05
033364-266	112	9203799	n/a	Mexico	Published	6/29/12
033364-273	112	35632A	25705	Philippines	Issued	09/18/08
033364-277	112	85/7576	85/7576	South Africa	Issued	10/10/05
033364-264	112	700881/86	29,068	South Korea	Issued	10/10/05
033364-276	112	74104531	NI-32657	Taiwan	Issued	06/11/04
<b>Bioactive lipids: ceramides</b>						
033364-006	144	09/429,694	n/a	United States	Pending	n/a
033364-017	144	08/383,291	5,631,394	United States	Issued	5/20/14
033364-907	144	08/547,688	5,677,337	United States	Issued	2/2/14
033364-908	144	08/545,164	5,681,589	United States	Issued	2/2/14
033364-884	144	2,182,485	n/a	Canada	Pending	2/2/15
033364-912	144	07-520799	n/a	Japan	Pending	2/2/15
033364-889	144	00102434.8	n/a	Europe	Pending	2/2/15
033364-881	144	95910923.2	0742789	Austria	Issued	2/2/15
033364-882	144	18712/95	691886	Australia	Issued	2/2/15
033364-883	144	95910923.2	0742789	Belgium	Issued	2/2/15

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-941	144	95910923.2	0742789	Denmark	Issued	2/2/15
033364-891	144	963045	n/a	Finland	Pending	2/2/15
033364-892	144	95910923.2	0742789	France	Issued	2/2/15
033364-940	144	95010923.2	69518627.2	Germany	Issued	2/2/15
033364-896	144	95910923.2	0742789	Ireland	Issued	2/2/15
033364-897	144	95910923.2	0742789	Italy	Issued	2/2/15
033364-914	144	95910923.2	0742789	Luxembourg	Issued	2/2/15
033364-915	144	95910923.2	0742789	Netherlands	Issued	2/2/15
033364-916	144	19963224	19963224	Norway	Issued	2/2/15
033364-911	144	95910923.2	0742789	Portugal	Issued	2/2/15
033364-890	144	95910923.2	0742789	Spain	Issued	2/2/15
033364-910	144	95910923.2	0742789	Sweden	Issued	2/2/15
033364-885	144	95910923.2	0742789	Switzerland	Issued	2/2/15
033364-893	144	95910923.2	0742789	United Kingdom	Issued	2/2/15
033364-895	144	00 104 798.6	n/a	Hong Kong	Pending	2/2/15
033364-894	144	20000402211	0742789	Greece	Issued	2/2/15
<b>High ratio cephalosporin complexes</b>						
033388-200	154	08/105,764	5,415,867	United States	Issued	5/16/12
033388-201	154	US89/02224	n/a	PCT	National Phase	
<b>Non-irritating liposome gel (MOPE) for mucosal delivery</b>						
033364-134	166	758,276	5,200,393	United States	Issued	4/6/10
033364-135	166	90904004.0	E 138 071	Austria	Issued	2/14/10
033364-137	166	90904004.0	0458894	Belgium	Issued	2/14/10

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-140	166	90904004.0	0458894	Denmark	Issued	2/14/10
033364-143	166	90904004.0	0458894	France	Issued	2/14/10
033364-139	166	90904004.0	69027022.4	Germany	Issued	2/14/10
033364-145	166	90904004.0	0458894	Italy	Issued	2/14/10
033364-147	166	90904004.0	0458894	Luxembourg	Issued	2/14/10
033364-148	166	90904004.0	0458894	Netherlands	Issued	2/14/10
033364-142	166	90904004.0	0458894	Spain	Issued	2/14/10
033364-149	166	90904004.0	0458894	Sweden	Issued	2/14/10
033364-138	166	90904004.0	0458894	Switzerland	Issued	2/14/10
033364-144	166	90904004.0	0458894	United Kingdom	Issued	2/14/10
033364-136	166	51736/90	639228	Australia	Issued	2/14/10
033364-146	166	700796/91	157,428	South Korea	Issued	7/30/13
<b>Adjuvant liposomes with CHS</b>						
033388-209	172	08/392,676	5,897,873	United States	Issued	4/27/16
033388-214	172	609,463	1,334,165	Canada	Issued	1/31/12
033388-211	172	89402344.9	E 113.472	Austria	Issued	8/25/09
033388-213	172	89402344.9	0356340	Belgium	Issued	8/25/09
033388-219	172	89402344.9	0356340	France	Issued	8/25/09
033388-216	172	89402344.9	68919173.1	Germany	Issued	8/25/09
033388-221	172	89402344.9	0356340	Greece	Issued	8/25/09
033388-222	172	89402344.9	0356340	Italy	Issued	8/25/09
033388-223	172	89402344.9	0356340	Luxembourg	Issued	8/25/09
033388-225	172	89402344.9	0356340	Netherlands	Issued	8/24/09
033388-218	172	89402344.9	0356340	Spain	Issued	8/25/09
033388-227	172	89402344.9	0356340	Sweden	Issued	8/25/09

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033388-215	172	89402344.9	0356340	Switzerland	Issued	8/25/09
033388-220	172	89402344.9	0356340	United Kingdom	Issued	8/25/09
033388-228	172	9791927.8	9791927.8	Singapore	Issued	2/24/17
033388-212	172	42214/89	631377	Australia	Issued	8/24/09
033388-224	172	923514	182481	Mexico	Issued	6/26/12
033388-226	172	230424	230424	New Zealand	Issued	8/24/05
<b>IF Gels</b>						
033364-673	174	08/315,988	5,820,848	United States	Issued	10/13/15
033364-674	174	08/881,651	6,086,851	United States	Issued	1/12/10
033364-682	174	2,073,431	2,073,431	Canada	Issued	1/11/11
033364-694	174	03-503398	3131923	Japan	Issued	1/11/11
033364-678	174	91903087.4	E146074	Austria	Issued	1/11/11
033364-681	174	91903087.4	0510086	Belgium	Issued	1/11/11
033364-683	174	91903087.4	0510086	Denmark	Issued	1/11/11
033364-688	174	91903087.4	0510086	France	Issued	1/11/11
033364-684	174	91903087.4	69123568.6	Germany	Issued	1/11/11
033364-690	174	91903087.4	3022701	Greece	Issued	1/11/11
033364-692	174	0086/91	81344	Ireland	Issued	1/11/11
033364-693	174	91903087.4	0510086	Italy	Issued	1/11/11
033364-697	174	91903087.4	0510086	Luxembourg	Issued	1/11/11
033364-700	174	91903087.4	0510086	Netherlands	Issued	1/10/11
033364-701	174	19922735	305535	Norway	Issued	1/11/11
033364-705	174	91903087.4	2096646	Spain	Issued	1/11/11
033364-706	174	91903087.4	0510086	Sweden	Issued	1/11/11
033364-707	174	91903087.4	0510086	Switzerland	Issued	1/11/11



BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-689	174	91903087.4	0510086	United Kingdom	Issued	1/11/11
033388-492	174	93924329.1	0665743	United Kingdom	Issued	10/13/13
033364-691	174	98106750.0	1007499	Hong Kong	Issued	1/10/11
033364-679	174	71817/91	652,552	Australia	Issued	1/11/11
033364-699	174	923791	188472	Mexico	Issued	1/12/10
033364-698	174	9306373	196433	Mexico	Issued	10/13/13
033364-703	174	277393	277393	New Zealand	Issued	10/13/09
033364-696	174	701330/95	0315215	South Korea	Issued	10/13/13
<b>Adjuvant liposomes</b>						
033388-231	179	08/452,549	5,916,588	United States	Issued	1/26/05
033388-233	179	07/485,388	6,090,406	United States	Issued	7/18/17
033388-232	179	923288	183096	Mexico	Issued	8/25/09
<b>Loading amino acids or peptides into liposomes using a pH gradient</b>						
033364-638	181	07/896,509	5,380,531	United States	Issued	1/10/12
033364-654	181	03-514831	n/a	Japan	Pending	7/25/11
033364-640	181	91915597.8	E136,456	Austria	Issued	7/25/11
033364-642	181	91915597.8	0555229	Belgium	Issued	7/25/11
033364-646	181	91915597.8	0555229	Denmark	Issued	7/25/11
033364-649	181	91915597.8	0555229	France	Issued	7/25/11
033364-645	181	91915597.8	69120089.0	Germany	Issued	7/25/11
033364-651	181	91915597.8	3020686	Greece	Issued	7/25/11
033364-653	181	91915597.8	0555229	Italy	Issued	7/25/11
033364-655	181	91915597.8	0555229	Luxembourg	Issued	7/25/11

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-656	181	91915597.8	0555229	Netherlands	Issued	7/25/11
033364-648	181	91915597.8	2089227	Spain	Issued	7/25/11
033364-643	181	91915597.8	0555229	Sweden	Issued	7/25/11
033364-644	181	91915597.8	0555229	Switzerland	Issued	7/25/11
033364-650	181	91915597.8	0555229	United Kingdom	Issued	7/25/11
033364-652	181	98106742.1	1007497	Hong Kong	Issued	7/24/11
033364-641	181	84365/91	660288	Australia	Issued	7/25/11
<b>Lung surfactant</b>						
033388-234	183	08/442,079	5,614,216	United States	Issued	3/25/14
033388-239	183	2,093,133	2,093,133	Canada	Issued	10/17/11
033388-249	183	04-500759	3171445	Japan	Issued	10/17/11
033388-236	183	91920210.1	0553272	Austria	Issued	10/17/11
033388-238	183	91920210.1	0553272	Belgium	Issued	10/17/11
033388-242	183	91920210.1	0553272	Denmark	Issued	10/17/11
033388-245	183	91920210.1	0553272	France	Issued	10/17/11
033388-241	183	91920210.1	0553272	Germany	Issued	10/17/11
033388-247	183	20000401896	0553272	Greece	Issued	10/17/11
033388-248	183	91920210.1	0553272	Italy	Issued	10/17/11
033388-251	183	91920210.1	0553272	Luxembourg	Issued	10/17/11
033388-252	183	91920210.1	0553272	Netherlands	Issued	10/17/11
033388-244	183	91920210.1	2146580	Spain	Issued	10/17/11
033388-253	183	91920210.1	0553272	Sweden	Issued	10/17/11
033388-240	183	91920210.1	0553272	Switzerland	Issued	10/17/11
033388-246	183	91920210.1	0553272	United Kingdom	Issued	10/17/11

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033388-237	183	89291/91	650303	Australia	Issued	10/17/11
033388-250	183	701000/93	181,309	South Korea	Issued	10/17/11
<b>Liposomal PGE1</b>						
033388-059	186	08/333,975	5,811,118	United States	Issued	9/22/15
033388-067	186	2,108,788	2,108,788	Canada	Issued	5/7/12
033388-068	186	2,175,896	n/a	Canada	Pending	11/3/14
033388-106	186	04-512039	n/a	Japan	Pending	5/7/12
033388-090	186	07-513378	n/a	Japan	Pending	11/3/14
033388-062	186	92401262.8	0512916	Austria	Issued	5/6/12
033388-063	186	95900504.2	E 191.141	Austria	Issued	11/3/14
033388-065	186	92401262.8	0512916	Belgium	Issued	5/6/12
033388-066	186	95900504.2	0726763	Belgium	Issued	11/3/14
033388-073	186	92401262.8	0512916	Denmark	Issued	5/6/12
033388-074	186	95900504.2	0726763 DK	Denmark	Issued	11/3/14
033388-079	186	92401262.8	0512916	France	Issued	5/6/12
033388-080	186	95900504.2	0726763	France	Issued	11/3/14
033388-071	186	92401262.8	69228332.3	Germany	Issued	5/6/12
033388-072	186	95900504.2	69423773.6	Germany	Issued	11/3/14
033388-083	186	92401262.8	3029641	Greece	Issued	5/6/12
033388-084	186	95900504.2	0726763	Greece	Issued	11/3/14
033388-085	186	921461	n/a	Ireland	Pending	5/7/12
033388-086	186	95900504.2	0726763	Ireland	Issued	11/3/14
033388-087	186	92401262.8	0512916	Italy	Issued	5/6/12
033388-088	186	95900504.2	0726763	Italy	Issued	11/3/14
033388-092	186	92401262.8	0512916	Luxembourg	Issued	5/6/12

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033388-093	186	95900504.2	0726763	Luxembourg	Issued	11/3/14
033388-096	186	92401262.8	0512916	Netherlands	Issued	5/6/12
033388-097	186	95900504.2	0726763	Netherlands	Issued	11/3/14
033388-098	186	19934016	306048	Norway	Issued	5/7/12
033388-099	186	19961778	312809	Norway	Issued	11/3/14
033388-100	186	92401262.8	0512916	Portugal	Issued	5/6/12
033388-101	186	95900504.2	0726763	Portugal	Issued	11/3/14
033388-077	186	92401262.8	0512916	Spain	Issued	5/6/12
033388-078	186	95900504.2	0726763	Spain	Issued	11/3/14
033388-102	186	92401262.8	0512916	Sweden	Issued	5/6/12
033388-103	186	95900504.2	0726763	Sweden	Issued	11/3/14
033388-069	186	92401262.8	0512916	Switzerland	Issued	5/6/12
033388-070	186	95900504.2	0726763	Switzerland	Issued	11/3/14
033388-081	186	92401262.8	0512916	United Kingdom	Issued	5/6/12
033388-082	186	95900504.2	0726763	United Kingdom	Issued	11/3/14
033388-064	186	20273/92	664704	Australia	Issued	5/7/12
033388-094	186	9202131	203959	Mexico	Issued	5/7/12
033388-095	186	948579	n/a	Mexico	Published	11/4/14
033388-105	186	94/8730	94/8730	South Africa	Issued	11/4/14
033388-091	186	93-703258	300772	South Korea	Issued	5/7/12
033388-089	186	702299/96	0355246	South Korea	Issued	11/3/14
<b>Method to make MLVs reproducibly</b>						
033364-900	192	08/253,145	5,540,936	United States	Issued	7/30/13
033364-904	192	2,159,596	n/a	Canada	Pending	4/4/14

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-905	192	06-522452	n/a	Japan	Pending	4/4/14
033364-902	192	94914024.8	n/a	Europe	Pending	4/4/14
033364-903	192	66251/94	676906	Australia	Issued	4/4/14
033364-906	192	704156/95	0315213	South Korea	Issued	4/4/14
<b>Process for making liposomes of a controlled size by ethanol removal/dilution</b>						
033364-708	193	08/442,077	6,596,305	United States	Issued	7/8/13
033364-712	193	2,166,465	n/a	Canada	Pending	7/8/14
033364-721	193	07-504185	n/a	Japan	Pending	7/8/14
033364-710	193	94921494.4	E 199.640	Austria	Issued	7/8/14
033364-711	193	94921494.4	0707472	Belgium	Issued	7/8/14
033364-713	193	94921494.4	0707472	Denmark	Issued	7/8/14
033364-715	193	94921494.4	0707472	France	Issued	7/8/14
033364-716	193	94921494.4	69426884.4	Germany	Issued	7/8/14
033364-718	193	20010400673	0707472	Greece	Issued	7/8/14
033364-719	193	94921494.4	0707472	Ireland	Issued	7/8/14
033364-720	193	94921494.4	0707472	Italy	Issued	7/8/14
033364-722	193	94921494.4	0707472	Luxembourg	Issued	7/8/14
033364-723	193	94921494.4	0707472	Netherlands	Issued	7/8/14
033364-724	193	94921494.4	0707472	Portugal	Issued	7/8/14
033364-725	193	94921494.4	2154680	Spain	Issued	7/8/14
033364-726	193	94921494.4	0707472	Sweden	Issued	7/8/14
033364-727	193	94921494.4	0707472	Switzerland	Issued	7/8/14
033364-717	193	94921494.4	0707472	United Kingdom	Issued	7/8/14

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
<b>Fusogenic (DODAP) liposomes where positive lipid is flipped inside via pH gradient</b>						
033364-868	197	08/226,642	5,552,155	United States	Issued	9/3/13
033364-872	197	2,187,748	n/a	Canada	Pending	4/12/14
033364-874	197	07-526306	n/a	Japan	Pending	4/12/14
033388-519	197	94919976.4	0758883	Denmark	Issued	4/12/14
033364-873	197	964083	n/a	Finland	Pending	4/12/14
033388-526	197	94919976.4	0758883	France	Issued	4/12/14
033388-525	197	94919976.4	0758883	Germany	Issued	4/12/14
033388-524	197	94919976.4	0758883	Ireland	Issued	4/12/14
033388-523	197	94919976.4	0758883	Italy	Issued	4/12/14
033388-522	197	94919976.4	0758883	Netherlands	Issued	4/12/14
033364-876	197	19964284	n/a	Norway	Pending	4/12/14
033388-521	197	94919976.4	0758883	Spain	Issued	4/12/14
033388-520	197	94919976.4	0758883	Switzerland	Issued	4/12/14
033388-527	197	94919976.4	0758883	United Kingdom	Issued	4/12/14
033364-871	197	70915/94	689479	Australia	Issued	4/12/14
033364-877	197	268146	268146	New Zealand	Issued	4/12/14
033364-875	197	705605/96	0315132	South Korea	Issued	4/12/14
<b>Liposomal defensins (indolicidin)</b>						
033364-917	202	08/449,598	5,766,624	United States	Issued	6/16/15
033364-923	202	2,172,955	n/a	Canada	Pending	10/25/14
033364-933	202	07-512759	n/a	Japan	Pending	10/25/14
033364-920	202	94932006.3	E 193.203	Austria	Issued	10/25/14
033364-922	202	94932006.3	0725629	Belgium	Issued	10/25/14
033364-926	202	94932006.3	0725629	Denmark	Issued	10/25/14

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-928	202	94932006.3	0725629	France	Issued	10/25/14
033364-925	202	94 932 006.3	69424680.8	Germany	Issued	10/25/14
033364-930	202	20000401946	0725629	Greece	Issued	10/25/14
033364-931	202	94932006.3	0725629	Ireland	Issued	10/25/14
033364-932	202	94932006.3	0725629	Italy	Issued	10/25/14
033364-935	202	94932006.3	0725629	Luxembourg	Issued	10/25/14
033364-937	202	94932006.3	0725629	Netherlands	Issued	10/25/14
033364-938	202	94932006.3	0725629	Portugal	Issued	10/25/14
033364-927	202	94932006.3	0725629	Spain	Issued	10/25/14
033364-939	202	94932006.3	0725629	Sweden	Issued	10/25/14
033364-924	202	94932006.3	0725629	Switzerland	Issued	10/25/14
033364-929	202	94932006.3	0725629	United Kingdom	Issued	10/25/14
033364-921	202	80888/94	680702	Australia	Issued	10/25/14
033364-936	202	928236	192153	Mexico	Issued	10/25/14
<b>Interdigitation</b>						
033364-781	203	08/339,964	5,882,678	United States	Issued	3/16/16
033364-796	203	07-514532	n/a	Japan	Pending	11/15/14
033364-783	203	95901236.0	0729352	Austria	Issued	11/15/14
033364-785	203	95901236.0	0729352	Belgium	Issued	11/15/14
033364-787	203	95901236.0	0729352	Denmark	Issued	11/15/14
033364-789	203	962080	n/a	Finland	Pending	11/15/14
033364-790	203	95901236.0	0729352	France	Issued	11/15/14
033364-791	203	P69416425.9	0729352	Germany	Issued	11/15/14
033364-793	203	95901236.0	3030123	Greece	Issued	11/15/14
033364-794	203	95901236.0	0729352	Ireland	Issued	11/15/14

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-795	203	95901236.0	0729352	Italy	Issued	11/15/14
033364-798	203	95901236.0	0729352	Luxembourg	Issued	11/15/14
033364-800	203	95901236.0	0729352	Netherlands	Issued	11/15/14
033364-801	203	19961949	312808	Norway	Issued	11/15/14
033364-802	203	95901236.0	0729352	Portugal	Issued	11/15/14
033364-803	203	95901236.0	0729352	Spain	Issued	11/15/14
033364-804	203	95901236.0	0729352	Sweden	Issued	11/15/14
033364-805	203	95901236.0	0729352	Switzerland	Issued	11/15/14
033364-792	203	95901236.0	0729352	United Kingdom	Issued	11/15/14
033364-784	203	10555/95	681469	Australia	Issued	11/15/14
033364-799	203	9408911	194774	Mexico	Issued	11/16/14
<b>NAPE fusogenic liposomes</b>						
033364-105	213	08/951,056	6,120,797	United States	Issued	10/15/16
033364-106	213	09/487,053	6,294,191	United States	Issued	10/15/16
033364-109	213	2,276,269	n/a	Canada	Pending	10/15/17
033364-111	213	97945550.8	n/a	Europe	Pending	10/15/17
033364-110	213	PV 2380-99	n/a	Czech Republic	Published	10/15/17
033364-112	213	P 00 00522	n/a	Hungary	Pending	10/15/17
033364-114	213	P19993257	n/a	Norway	Pending	10/15/17
033364-117	213	PV993-99	PV993-99	Slovak Republic	Issued	10/15/17
033364-116	213	9903059-5	66518	Singapore	Issued	10/15/17
033364-108	213	46723/97	725257	Australia	Issued	10/15/17
033364-113	213	130822	n/a	Israel	Pending	10/15/17
033364-115	213	336538	336538	New Zealand	Issued	10/15/17



BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
<b>Peptide lipid conjugates for triggered release</b>						
033364-036.001	215	08/950,618	6,087,325	United States	Issued	10/15/16
033364-037	215	09/168,010	6,143,716	United States	Issued	10/15/16
033364-008	215	09/343,650	6,339,069	United States	Issued	10/15/16
033364-040	215	US00/16248	n/a	PCT	National Phase	n/a
033364-042	215	2,276,267	n/a	Canada	Pending	10/15/17
033388-417	215	2,376,859	n/a	Canada	Pending	6/13/20
033388-416	215	2001-505954	n/a	Japan	Pending	6/13/20
033388-418	215	00942784.0	n/a	Europe	Pending	6/13/20
033364-043	215	PV 2376-99	n/a	Czech Republic	Published	10/15/17
033364-044	215	P0000150	n/a	Hungary	Published	10/15/17
033364-046	215	19993258	n/a	Norway	Pending	10/15/17
033364-049	215	PV992-99	n/a	Slovak Republic	Pending	10/15/17
033364-041	215	48207/97	725376	Australia	Issued	10/15/17
033388-420	215	57355/00	n/a	Australia	Pending	6/13/20
033364-045	215	130823	n/a	Israel	Pending	10/15/17
033388-419	215	2002/000020	n/a	Mexico	Pending	6/13/20
033364-047	215	336539	336539	New Zealand	Issued	10/15/17
033364-048	215	9903060-3	66519	Singapore	Issued	10/15/17
<b>Lipocores</b>						
033364-005	218	09/314,338	6,500,461	United States	Issued	5/19/19
033364-055	218	2,332,545	n/a	Canada	Pending	5/19/19

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033364-066	218	2000-549215	n/a	Japan	Pending	5/19/19
033364-060	218	99925661.3	n/a	Europe	Pending	5/19/19
033364-070	218	20005832	n/a	Norway	Pending	5/19/19
033364-077	218	PV 2000-1742	n/a	Slovak Republic	Pending	11/17/20
033364- 060.001	218	01106267.2	n/a	Hong Kong	Pending	5/19/19
033364-053	218	4190699-745015	n/a	Australia	Pending	5/19/19
033364-059	218	1447/2000	n/a	Egypt	Pending	5/19/14
033364-064	218	2000,00633	n/a	India	Pending	5/19/13
033364-068	218	0011361	n/a	Mexico	Pending	5/19/19
033364-073	218	198/2000	n/a	Paraguay	Pending	11/17/15
033364-075	218	01 22 0022	n/a	Saudi Arabia	Pending	n/a
033364-067	218	2000-7013002	n/a	South Korea	Pending	5/19/19
033364-079	218	88108307	n/a	Taiwan	Pending	5/20/19
033364-078	218	00/3435	200003435	Turkey	Issued	5/19/14
033364-080	218	IAP 2000 0936	n/a	Uzbekistan	Pending	5/19/19
<b>Emulsion entrapment method</b>						
033388-328	221	09/914,615	n/a	United States	Pending	3/1/20
033388-313	221	2362485		Canada	Pending	3/1/20
033388-319	221	2000-602035	n/a	Japan	Pending	3/1/20
033388-316	221	00915983.1	1156783	Europe	Published	3/1/20
033388-315	221	2001-3103	n/a	Czech Republic	Pending	3/1/20
033388-325	221	20014231	n/a	Norway	Pending	3/1/20
033388-326	221	P-351487	n/a	Poland	Pending	3/1/20
033388-312	221	PI0008711-4	n/a	Brazil	Pending	3/1/20

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033388-321	221	145,117	n/a	Israel	Pending	3/1/20
033388-323	221	2001/008804	n/a	Mexico	Pending	3/1/20
033388-322	221	2001-7011174	n/a	South Korea	Pending	3/1/20
<b>Lupus assay patents</b>						
033364-119	222	US00/26067	n/a	PCT	National Phase	n/a
<b>Modular targeted delivery using electrostatic binding moiety to which a targeting ligand is attached</b>						
033388-509	224	10/130,951	n/a	United States	Pending	11/17/20
033388-503	224	2,391,606	n/a	Canada	Pending	11/17/20
033388-505	224	00980515.1	n/a	Europe	Pending	11/17/20
033388- 505.001	224	03101361.6	n/a	Hong Kong	Pending	2/21/23
033388-504	224	2001-539422	n/a	Japan	Pending	11/17/20
033364-122	224	US00/31712	n/a	PCT	National Phase	n/a
<b>Gel Hydration</b>						
033388-582	None	2003205048	n/a	Australia	Pending	n/a
033388-584	None	Not yet assigned [based from PCT/US03/00377]	n/a	Canada	Pending	n/a
033388-583	None	03703716.5	n/a	Europe	Pending	n/a
033388-589	None	10/500,932	n/a	United States	Pending	n/a
033388-579	None	2003205049	n/a	Australia	Pending	n/a
033388-581	None	Not yet assigned [based from PCT/US03/00380]	n/a	Canada	Pending	n/a

BDSM Ref. No.	Family	Application No.	Patent No.	Country	Status	Expiration Date
033388-580	None	03703717.3	n/a	Europe	Pending	n/a
033388-590	None	10/500,933	n/a	United States	Pending	n/a
033388-585	None	2003207462	n/a	Australia	Pending	n/a
033388-587	None	Not yet assigned [based from PCT/US03/00373]	n/a	Canada	Pending	n/a
033388-586	None	03705670.2	n/a	Europe	Pending	n/a
033388-588	None	10/500,977	n/a	United States	Pending	n/a

## Attachment A

<b>BDSM Ref. No.</b>	<b>Family</b>	<b>Application No.</b>	<b>Patent No.</b>	<b>Country</b>	<b>Status</b>	<b>Expiration Date</b>
033364-234	112	08/108,822	6,352,716	United States	Issued	3/5/19
033364-232	112	07/425,727	5,231,112	United States	Issued	1/26/05
033364-233	112	07/758,587	5,288,499	United States	Issued	1/26/05
033364-234	112	08/108,822	6,352,716	United States	Issued	3/5/19
033364-006	144	09/429,694	n/a	United States	Pending	n/a
033364-017	144	08/383,291	5,631,394	United States	Issued	5/20/14
033364-907	144	08/547,688	5,677,337	United States	Issued	2/2/14
033364-908	144	08/545,164	5,681,589	United States	Issued	2/2/14
033388-200	154	08/105,764	5,415,867	United States	Issued	5/16/12
033364-134	166	758,276	5,200,393	United States	Issued	4/6/10
033388-209	172	08/392,676	5,897,873	United States	Issued	4/27/16
033364-673	174	08/315,988	5,820,848	United States	Issued	10/13/15
033364-674	174	08/881,651	6,086,851	United States	Issued	1/12/10
033388-231	179	08/452,549	5,916,588	United States	Issued	1/26/05
033388-233	179	07/485,388	6,090,406	United States	Issued	7/18/17
033364-638	181	07/896,509	5,380,531	United States	Issued	1/10/12
033388-234	183	08/442,079	5,614,216	United States	Issued	3/25/14
033388-059	186	08/333,975	5,811,118	United States	Issued	9/22/15
033364-900	192	08/253,145	5,540,936	United States	Issued	7/30/13
033364-708	193	08/442,077	6,596,305	United States	Issued	7/8/13
033364-868	197	08/226,642	5,552,155	United States	Issued	9/3/13
033364-917	202	08/449,598	5,766,624	United States	Issued	6/16/15
033364-781	203	08/339,964	5,882,678	United States	Issued	3/16/16
033364-105	213	08/951,056	6,120,797	United States	Issued	10/15/16

<b>BDSM Ref. No.</b>	<b>Family</b>	<b>Application No.</b>	<b>Patent No.</b>	<b>Country</b>	<b>Status</b>	<b>Expiration Date</b>
033364-106	213	09/487,053	6,294,191	United States	Issued	10/15/16
033364-036.001	215	08/950,618	6,087,325	United States	Issued	10/15/16
033364-037	215	09/168,010	6,143,716	United States	Issued	10/15/16
033364-008	215	09/343,650	6,339,069	United States	Issued	10/15/16
033364-005	218	09/314,338	6,500,461	United States	Issued	5/19/19
033388-328	221	09/914,615	n/a	United States	Pending	3/1/20
033388-509	224	10/130,951	n/a	United States	Pending	11/17/20
033388-589	None	10/500,932	n/a	United States	Pending	n/a
033388-590	None	10/500,933	n/a	United States	Pending	n/a
033388-588	None	10/500,977	n/a	United States	Pending	n/a